AMRI Awarded API Contract
AMRI has been awarded a seven-year contract for an active ingredient under clinical evaluation.
AMRI reported that its subsidiary, Albany Molecular Research, located in Holywell, Wales, United Kingdom, has been awarded a seven-year contract for the development and manufacture of an active ingredient under clinical evaluation by the Defense Science and Technology Laboratory, acting on behalf of the United Kingdom’s Secretary of State for Defense, the Department of National Defense of Canada, and Minister of Defense of the Kingdom of the Netherlands.
AMRI will initially work on the development and scale-up of the investigational drug, and the manufacture and supply for use during Phase I clinical trials. If the trials are successful, AMRI could become the commercial manufacturer of the product for distribution to the government partners of this contract, including the UK, the Netherlands, and Canada.
Source: AMRI
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
